Embecta Corp. engages in manufacturing and distributing medical devices used in the treatment of diabetes. The company is headquartered in Parsippany, New Jersey and currently employs 2,200 full-time employees. The company went IPO on 2022-03-21. The firm is focused on providing solutions to people living with diabetes. The firm has a portfolio of products, including a range of pen needles, syringes and safety injection devices, which are complemented by its digital application designed to assist people with managing their diabetes. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. The firm also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. In addition to pen needles, it sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. The company distributes its products through a variety of channels, including retail, hospitals, pharmacies and other institutional channels.